Pretomanid

Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB) . The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.

Product Specifications

CAS Number

[187235-37-6]

Product Name Alternative

PA-824; (S) -PA 824

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/PA-824.html

Purity

99.97

Solubility

DMSO : 125 mg/mL (ultrasonic) |Ethanol : 12.5 mg/mL (ultrasonic)

Smiles

FC(F)(F)OC(C=C1)=CC=C1CO[C@@H]2COC3=NC([N+]([O-])=O)=CN3C2

Molecular Formula

C14H12F3N3O5

Molecular Weight

359.26

Precautions

H315, H319, H335

References & Citations

[1]Stover CK, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000 Jun 22;405 (6789) :962-6.|[2]Lenaerts AJ, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005 Jun;49 (6) :2294-301.|[3]Manjunatha UH, et al. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother. 2006 Oct;50 (10) :3350-4.